Close Menu

ProteinSimple

NEW YORK (GenomeWeb) – Bio-Techne today announced a deal to buy protein analysis technology firm ProteinSimple for $300 million in cash.

ProteinSimple has appointed Joe Keegan and Chris van Ingen to its board of directors.
Keegan was previously the CEO of ForteBio and Molecular Devices.

Quanterix this week launched a commercial, research-use-only version of its Single Molecule Array, Simoa, platform.

ProteinSimple said this week that it has hired Terry Salyer as vice president of sales.

By Adam Bonislawski
A team led by Stanford University researchers has developed a method for predicting response to cancer therapies based on cellular signaling protein dynamics and changes in tumor size.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.